About us

OncoOne is a biotech start-up dedicated to developing innovative therapeutics to treat patients with solid tumors and inflammatory conditions, founded by three individuals with a long history in drug development and oncology research from the pharmaceutical industry.

The aim of OncoOne is to develop novel anti-cancer medicines that meet serious unmet medical needs in oncology as well as adjacent indications, such as inflammation. Our passion for science is at the core of everything we do to build a differentiated therapeutic pipeline. Our entrepreneurial spirit enables us to link innovation with nimble operations to fulfill corporate strategies.

read more
Nov 17, 2021

 

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

OncoOne and GenScript ProBio have entered into an agreement for the cell line development, drug substance and drug product manufacturing of therapeutic and diagnostic monoclonal antibodies (mAbs) directed against the promising immuno-oncology target, oxidized macrophage migration inhibitory factor (oxMIF). The companies will combine their respective expertise in drug discovery and manufacturing to bring the resulting mAb candidates into the clinic.

We are a team of experienced professionals.

Randolf Kerschbaumer, PhD

Co-Founder & Chief Executive Officer

Randolf has more than 20 years of experience in academic and big pharma R&D and acquired detailed knowledge of the entire drug development process, from early drug screening to clinical development. He leads the executive management team, patenting, and investor relations.

Michael Thiele, PhD

Co-Founder & Chief Scientific Officer

Michael is a renowned expert in immunology, tumor biology, biomarkers and the development of biologics. He leads the OncoOne biology team. Michael is responsible for leading the teams who conduct our preclinical studies and for conducting research on drug/target mechanisms in biological systems.

Alexander Schinagl, PhD

Co-Founder & Chief Technology Officer

Alexander has a broad knowledge of molecular biology, biochemistry and cell biology techniques in the field of oncology and inflammation and he leads the OncoOne protein sciences team. Alexander oversees the implementation of the technologies used for the production and analysis of the company’s therapeutics.

Brent Meadows

OncoOne US Co-Founder & Chief Business Officer

Brent has over 20 years of oncology pipeline and launch marketing commercialization including having facilitated successful in- and out-licensing partnerships at both large pharma and small biotech companies.  He leads the business development, partnering, commercialization strategy of OncoOne’s pipeline assets, and US operations.

read more

What would a strong team be without excellent partners.

read more